Literature DB >> 4788038

Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation.

V Eisen, C Loveday.   

Abstract

1. The inhibition by suramin of complement components, and of blood clotting, fibrinolytic, and plasma kinin forming factors depended on the conditions of the assay and on the substrates used.2. Haemolysis by complement was more effectively inhibited in red blood cell suspensions, than in agarose gel plates. In esterolytic tests, the activation of component 1 (C1) to C1 esterase was significantly inhibited by 0.1-0.3 mM suramin, and the activity of C1 esterase by 0.5 mM suramin.3. Part of the anticoagulant effect of suramin is due to inhibition of the action of thrombin on fibrinogen.4. Suramin did not inhibit fibrin degradation by the fibrinolytic system in plasma. In esterolytic tests, the activation of plasminogen was more potently inhibited than the activity of plasmin.5. Activation of plasma kallikrein, measured either by kinin formation or by esterolysis, was inhibited by 0.1-0.3 mM suramin. Active plasma kallikrein was inhibited by 0.3-0.5 mM suramin. Pancreatic kallikrein was weakly inhibited, and urinary kallikrein not at all.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4788038      PMCID: PMC1776599          DOI: 10.1111/j.1476-5381.1973.tb08544.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  Studies on plasma kallikrein and its relationship to plasmin.

Authors:  M E WEBSTER; J V PIERCE
Journal:  J Pharmacol Exp Ther       Date:  1960-12       Impact factor: 4.030

2.  The kaolin clotting time; a rapid one-stage method for diagnosis of coagulation defects.

Authors:  J MARGOLIS
Journal:  J Clin Pathol       Date:  1958-09       Impact factor: 3.411

3.  Observations on intrinsic kinin-forming factors in human plasma: the effect of acid, acetone, chloroform, heat and euglobulin separation on kinin formation.

Authors:  V Eisen
Journal:  J Physiol       Date:  1963-05       Impact factor: 5.182

4.  Diagnostic complement fixation. I. A method.

Authors:  A G OSLER; J H STRAUSS; M M MAYER
Journal:  Am J Syph Gonorrhea Vener Dis       Date:  1952-03

5.  Studies on suramin; the action of the drug on some enzymes.

Authors:  E D WILLS; A WORMALL
Journal:  Biochem J       Date:  1950-08       Impact factor: 3.857

6.  Reaction mechanism of the alternative pathway of complement fixation.

Authors:  P J Lachmann; P Nicol
Journal:  Lancet       Date:  1973-03-03       Impact factor: 79.321

7.  Intrinsic activation of plasma kinin formation and complement.

Authors:  V Eisen; C Loveday
Journal:  Int Arch Allergy Appl Immunol       Date:  1973

8.  Suramin--a potent reversible and competitive inhibitor of complement systems.

Authors:  J S Fong; R A Good
Journal:  Clin Exp Immunol       Date:  1972-01       Impact factor: 4.330

9.  An analogue of guinea pig C8: in vitro generation and inhibitory activity.

Authors:  R L Stolfi
Journal:  J Immunol       Date:  1970-05       Impact factor: 5.422

10.  Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7.

Authors:  R A Thompson; P J Lachmann
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

View more
  13 in total

1.  Anion channel blockers cause apparent inhibition of exocytosis by reacting with agonist or secretory product, not with cell.

Authors:  J G Vostal; D M Reid; C E Jones; N R Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

Review 2.  100 Years of Suramin.

Authors:  Natalie Wiedemar; Dennis A Hauser; Pascal Mäser
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  Inhibition of immune complex-mediated activation of complement. Effects of agents modulating activation of, and the activated C1 complex.

Authors:  D S Fletcher; T Y Lin
Journal:  Inflammation       Date:  1980-03       Impact factor: 4.092

4.  Suramin stimulates renal growth in the rat.

Authors:  L Selmeci; K Szepesházi; E Pósch; L Hársing
Journal:  Experientia       Date:  1978-02-15

5.  Suramin prevents duck hepatitis B virus infection in vivo.

Authors:  W B Offensperger; S Offensperger; E Walter; H E Blum; W Gerok
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

6.  Suramin stimulates B-lymphocyte proliferation in the mouse.

Authors:  T L Vischer
Journal:  Agents Actions       Date:  1976-07

7.  Comparative effects of drugs on four paw oedema models in the rat.

Authors:  D K Gemmell; J Cottney; A J Lewis
Journal:  Agents Actions       Date:  1979-04

8.  Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.

Authors:  V Ellis; K Danø
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

9.  Alpha-hemolysin from Escherichia coli uses endogenous amplification through P2X receptor activation to induce hemolysis.

Authors:  Marianne Skals; Niklas R Jorgensen; Jens Leipziger; Helle A Praetorius
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-18       Impact factor: 11.205

10.  Modulation of CD4 by suramin.

Authors:  P D Allen; D H Johnston; M G Macey; N S Williams; A C Newland
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.